Pfizer Expands Income Eligibility For Drug Program

Pfizer Expands Income Eligibility For Drug Program
The regional headquarters of Pfizer in Vanha Munkkiniemi, Helsinki, Finland. Lauri Silvennoinen / Wikimedia Commons CC BY-SA 3.0
Share on Facebook
Share on Twitter
Share on Google+
Share on LinkedIn
Pin to Pinterest
Share on StumbleUpon
What's This?

Pfizer has announced that it will double the allowable income level for its patient assistance program known as Pfizer RxPathways, effective immediately. This is in hopes of helping more patients pay their out-of-pocket costs for various prescription medicines.


With the change in allowable income level, Pfizer is making over 40 medicines free to eligible patients earning up to four times the Federal Poverty Level (FPL) adjusted for family size ($47,080 for a single person; $97,000 for a family of four). Pfizer Executive Vice President for Corporate Affairs Sally Susman explains, “While patient assistance is not a permanent solution, it is a necessary step for helping to solve some of the high co-pay issues that some patients face.”

The Pfizer RxPathways program is all about helping all kinds of patients, whether they have health insurance or not. And in fact, during the last five years, Pfizer has managed to help almost 2.5 million uninsured and underinsured patients gain access to over 30 million Pfizer prescriptions. Some of the medicines made available through the Pfizer RxPathways program inclue Accupril, Arthrotec, Bacitracin, Benefix, Celebrex, Caduet, Camptosar, Cortef, Corvert, Genotropin, Levoxyl, Mycobutin, Nardil, Prevnar 13, Procardia, Vistaril and more. Pfizer has been helping individuals gain access to prescription medicine for more than 25 years.

Today, the Pfizer RxPathways program not only provides free medicine to eligible individuals. The program also offers a discount of 35% to 50% on the retail price of Pfizer medicines to uninsured patients, insurance counseling, co-pay cards for those with insurance as well as referrals to other industry resources.

Like us on Facebook